JB
Julià Blanco
Universitat de Vic - Universitat Central de Catalunya, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat de Barcelona
Research areas: Medicine · Infectious Diseases · HIV Research and Treatment · SARS-CoV-2 and COVID-19 Research · HIV/AIDS drug development and treatment
0000-0002-2225-0217
Employment
-
AlbaJuna Therapeutics, S.L. CEO2016 - 2023
-
Universitat de Vic - Universitat Central de Catalunya Associate Professor2014 - Present
-
Universitat Autònoma de Barcelona Associate professor2014 - 2018
-
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Senior Researcher1999 - Present
-
IrsiCaixa Institut de Recerca de la Sida1997 - Present
-
Universitat de Barcelona Col·laborador docent1993 - 1994
Education
-
Universitat de Barcelona PhD student1990 - 1994
Projects & Funding
Projects & funding information is unavailable.
Publications (272)
- First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial Save
- TARDBP as a regulator of HIV-1 assembly and infection: a review of targeting the viral capsid precursor Pr55Gag and limiting viral core entry Save
- Better and closer glycan-independent anti-V3 antibodies to help HIV-1 vaccine Save
- Pediatric long COVID is characterized by myeloid CCR6 suppression and immune dysregulation Save
- Multiple roles of humoral responses in the control of HIV infection Save
- Optimized <scp>ACE2</scp> ‐Fc fusion proteins with picomolar neutralization activity against highly evolved <scp>SARS</scp> ‐ <scp>CoV</scp> … Save
- Under the Radar: Immune Evasion, Pathogenesis and Control of HIV Infection Save
- Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters Save
- Tracking the soluble biomarkers of MIS-C and their association with clinical parameters and severity Save
- TARDBP as a Gatekeeper of HIV-1 Assembly and Infection: Targeting the Viral Capsid Precursor Pr55Gag and Limiting Viral Core Entry Save
- Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial Save
- Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters Save
- Immune Durability and Breakthrough Infections 15 Months After SARS-CoV-2 Boosters in People over 65: The IMMERSION Study Save
- Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection Save
- Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species Save
- A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model Save
- Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic Save
- Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections Save
- Isolation and structure elucidation of Dm-CVNH, a new cyanovirin-N homolog with activity against SARS-CoV-2 and HIV-1 Save
- Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes Save